OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
25 April 2023 - 4:00PM
OKYO Pharma Announces Activation of First Clinical Trial Site in
the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment
of Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an
ophthalmology-focused bio-pharmaceutical company which is
developing OK-101 to treat dry eye disease to address the
significant unmet need in this multi-billion-dollar market, today
announces the activation of the first clinical trial site in the
U.S. for its phase 2, multi-center, randomized, double-blinded,
placebo-controlled trial, evaluating the efficacy and safety of
OK-101 ophthalmic solution in subjects with dry eye disease. First
patient first visit is presently expected to occur within the next
two weeks.
“Our primary focus continues to be on advancing the clinical
development of OK-101 as a potential treatment option for dry eye
disease, a chronic ocular condition that affects roughly 700
million people worldwide,” said Gary S. Jacob, Ph.D., CEO of OKYO
Pharma. “With the activation of our first clinical site we are now
very close to the opening of the OK-101 phase 2 trial and are
looking forward to initiating enrollment and completing the trial
before the end of the year."
About OK-101OK-101 is a lipid conjugated
chemerin peptide antagonist of the ChemR23 G-protein coupled
receptor which is typically found on immune cells of the eye
responsible for the inflammatory response. OK-101 was developed
using a membrane-anchored-peptide (MAP) technology to produce a
novel long-acting drug candidate for treating dry eye disease.
OK-101 has been shown to produce anti-inflammatory and
pain-reducing activities in mouse models of dry eye disease and
corneal neuropathic pain; and is designed to combat washout through
the inclusion of the lipid ‘anchor’ contained in the candidate drug
molecule to enhance the residence time of OK-101 within the ocular
environment.
About OKYOOKYO Pharma Limited (LSE: OKYO;
NASDAQ: OKYO) is a life sciences company admitted to listing on
NASDAQ and on the standard segment of the Official List of the UK
Financial Conduct Authority and to trading on the main market for
listed securities of London Stock Exchange plc. OKYO is focusing on
the discovery and development of novel molecules to treat
inflammatory dry eye diseases and chronic pain. For further
information, please visit www.okyopharma.com.
Forward-Looking StatementsCertain statements
made in this announcement are forward-looking statements. These
forward-looking statements are not historical facts but rather are
based on the Company's current expectations, estimates, and
projections about its industry; its beliefs; and assumptions. Words
such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,'
'seeks,' 'estimates,' and similar expressions are intended to
identify forward-looking statements. These statements are not
guarantees of future performance and are subject to known and
unknown risks, uncertainties, and other factors, some of which are
beyond the Company's control, are difficult to predict, and could
cause actual results to differ materially from those expressed or
forecasted in the forward-looking statements. The Company cautions
security holders and prospective security holders not to place
undue reliance on these forward-looking statements, which reflect
the view of the Company only as of the date of this announcement.
The forward-looking statements made in this announcement relate
only to events as of the date on which the statements are made. The
Company will not undertake any obligation to release publicly any
revisions or updates to these forward-looking statements to reflect
events, circumstances, or unanticipated events occurring after the
date of this announcement except as required by law or by any
appropriate regulatory authority.For further information, please
visit the Company's website at www.okyopharma.com
The person who arranged for the release of this announcement on
behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive
Officer of OKYO.
Enquiries:
OKYO Pharma Limited |
Gary S. Jacob, Ph.D., Chief Executive Officer |
+44 (0)20 7495 2379 |
Investor
Relations |
Paul Spencer |
+44 (0)20 7495 2379 |
Optiva Securities
Limited (Broker) |
Robert Emmet |
+44 (0)20 3981 4173 |
|
|
|
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE
PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF
DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT)
REGULATIONS (SI 2019/310) (UK MAR). UPON THE PUBLICATION OF THIS
ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW
CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2023 to Apr 2024